Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans by Olkowicz, Mariola et al.
Olkowicz et al. J Transl Med            (2021) 19:6  
https://doi.org/10.1186/s12967-020-02663-8
RESEARCH
Multi-omic signatures of atherogenic 
dyslipidaemia: pre-clinical target identification 
and validation in humans
Mariola Olkowicz1,2* , Izabela Czyzynska‑Cichon2, Natalia Szupryczynska3, Renata B. Kostogrys4, 
Zdzislaw Kochan3, Janusz Debski5, Michal Dadlez5, Stefan Chlopicki2,6 and Ryszard T. Smolenski1*
Abstract 
Background: Dyslipidaemia is a major risk factor for atherosclerosis and cardiovascular diseases. The molecular 
mechanisms that translate dyslipidaemia into atherogenesis and reliable markers of its progression are yet to be fully 
elucidated. To address this issue, we conducted a comprehensive metabolomic and proteomic analysis in an experi‑
mental model of dyslipidaemia and in patients with familial hypercholesterolemia (FH).
Methods: Liquid chromatography/mass spectrometry (LC/MS) and immunoassays were used to find out blood 
alterations at metabolite and protein levels in dyslipidaemic  ApoE−/−/LDLR−/− mice and in FH patients to evaluate 
their human relevance.
Results: We identified 15 metabolites (inhibitors and substrates of nitric oxide synthase (NOS), low‑molecular‑weight 
antioxidants (glutamine, taurine), homocysteine, methionine, 1‑methylnicotinamide, alanine and hydroxyproline) and 
9 proteins (C‑reactive protein, proprotein convertase subtilisin/kexin type 9, apolipoprotein C‑III, soluble intercellular 
adhesion molecule‑1, angiotensinogen, paraoxonase‑1, fetuin‑B, vitamin K‑dependent protein S and biglycan) that 
differentiated FH patients from healthy controls. Most of these changes were consistently found in dyslipidaemic mice 
and were further amplified if mice were fed an atherogenic (Western or low‑carbohydrate, high‑protein) diet.
Conclusions: The alterations highlighted the involvement of an immune‑inflammatory response system, oxidative 
stress, hyper‑coagulation and impairment in the vascular function/regenerative capacity in response to dyslipidaemia 
that may also be directly engaged in development of atherosclerosis. Our study further identified potential biomark‑
ers for an increased risk of atherosclerosis that may aid in clinical diagnosis or in the personalized treatment.
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Background
Atherosclerosis, a major contributor to cardiovascular 
diseases (CVDs), is a pathogenic process with a com-
plex/multi-factorial nature [1, 2]. Its diverse causal 
factors that include age, male gender, smoking, high 
blood pressure, diabetes mellitus and, in particular, 
dyslipidaemia have been well recognized, although the 
underlying mechanisms of atherogenesis still remain 
not fully understood [3, 4]. The majority of studies on 
atherogenesis are focused on vascular plaque formation 
and structure [5], and the results are difficult to trans-
late into preventive markers in routine diagnostics and 
provide incomplete information concerning the mecha-
nisms. Therefore, the identification of novel blood bio-
chemical markers would be highly useful not only for 
a better understanding of the mechanisms involved 
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atherosclerosis progression and treatment. Several of 
such molecules for risk-stratification in atherosclero-
sis have been proposed, such as high-sensitivity car-
diac troponin T (hs-cTnT), C-reactive protein (CRP), 
soluble CD40 ligand (sCD40L), adiponectin, interleu-
kin-18 (IL-18), matrix metalloproteinase-9 (MMP-9), 
docosahexaenoic acid, glutamine and tyrosine [6–8], 
and some are under validation for use in clinical and 
research settings [9, 10]; however, none of these param-
eters are based on a comprehensive assessment of 
metabolomic and proteomic indices and, therefore, 
their implementation into clinical practice may not be 
adequate in all possible scenarios. There is a justified 
need to determine novel molecular indicators based on 
a broader spectrum of targets that alone, or in combi-
nation with existing ones, will provide better knowl-
edge of the operating mechanisms leading to disease 
progression and its accurate biomarkers.
Experimental models that reproduce the pathogenic 
steps of atherosclerosis beginning with dyslipidaemia 
could pave the way for the discovery of the pathomech-
anisms involved and, eventually, biomarkers [11, 12]. 
Double  ApoE−/− and  LDLR−/− knockout mice constitute 
a reliable model of atherogenesis that begins with dys-
lipidaemia leading to atherosclerotic plaques. This model 
resembles human pathophysiology of the disease, fea-
tured by endothelial dysfunction, vascular inflammation 
and appearance of advanced atherosclerotic plaques with 
their distribution within the vasculature and histological 
features similar to humans [13–15].  ApoE−/−/LDLR−/− 
mice display some advantages over single  ApoE−/− and 
 LDLR−/− knockouts as dyslipidaemia is evident even 
with a standard diet, and spontaneous atherosclerosis 
develops more rapidly [16]. Therefore, the research of 
risk factors related to atherosclerosis and its pathogenesis 
could benefit from the study of this model.
Recent technological advances, together with bioin-
formatics defined as the ‘omics’-based approaches (i.e., 
genomics, transcriptomics, proteomics and metabo-
lomics), enable global characterization, at multiple lev-
els (molecules/entire pathway), of complex biological 
systems and their changes in pathological processes [10, 
17]. Among them, metabolomics and proteomics repre-
sent the most promising tools for the discovery of novel 
serological biomarkers and increasing understanding of 
the complex processes in atherosclerosis development/
progression involved [18–23]. The number of reports 
using non-targeted or targeted metabolomics or prot-
eomics for the study of CVDs is ever increasing, but most 
of them with only few exceptions [24, 25] concentrate on 
a single-omics technique, while a comprehensive dataset 
of proteins as well as metabolites participating in a given 
disease is urgently needed [26–28].
In this work, an integrated metabolomic and proteomic 
analysis was performed using multi-platform analytical 
tools to identify the molecular signature of atherogenic 
dyslipidaemia in  ApoE−/−/LDLR−/− mice. The metabolic/
proteomic pathways related to biomarkers proposed 
were further explored to indicate possible targets for 
therapeutic intervention or prevention. That analysis was 
also followed by an investigation in patients with familial 
hypercholesterolemia (FH) and control subjects to vali-
date the discrimination performance of the selected mol-
ecules and confirm their clinical relevance.
Methods
Animals and experimental design
ApoE/LDLR double knockouts on a C57BL/6 back-
ground  (ApoE−/−/LDLR−/−) and wild-type C57BL/6 
(WT) female mice, originally obtained from the Jackson 
Laboratory (JAX, USA), were bred in house and at the 
age of 6–7  months used in this study (Additional file  1: 
Table S1). The animals were housed in a 12-h day-night 
cycle in environmentally controlled rooms and allowed 
free access to water and a standard chow diet. Whole 
blood was collected via cardiac puncture into chilled 
tubes (containing EDTA as an anticoagulant) and centri-
fuged (4000×g, 10  min) to obtain plasma samples. The 
samples were analysed for: (a) proteomic pattern changes 
using a mass spectrometry (MS)-based non-targeted 
approach, (b) metabolomic pattern changes using an 
MS-based targeted approach and (c) systemic alterations 
within the renin-angiotensin system (RAS).
For the survival experiment or evaluation of the effect 
of pro-atherogenic diets on plasma metabolomic pat-
tern (to verify whether specific changes will be further 
accelerated along with atherosclerosis progression), 
the mice were fed a commercial, cholesterol-free, pel-
leted diet (Sniff M-Z Spezialdiäten GmbH; Soest, Ger-
many) up to the age of 16–18  weeks. At this age, mice 
were weight-matched between groups (n = 42–49 (sur-
vival experiment) and n = 5–6 (metabolomics study) in 
each group) and fed AIN-93G-based diets: control diet 
(AIN) and experimental-Western or low-carbohydrate, 
high-protein (LCHP) diets for the next 8 weeks. Detailed 
compositions of the diets are provided in Additional 
file 1: Table S2, whereas the effects of dietary treatments 
on body and organ weight, as well as plasma biochemi-
cal markers, are presented in Additional file 1: Table S3. 
After 8 weeks of feeding (metabolomics study as well as 
an assessment of aortic atherosclerotic lesions), the mice 
were anaesthetized with ketamine/xylazine (100/10 mg/
kg body weight) given intraperitoneally and sacrificed by 
cervical dislocation. Blood samples were taken under 4-h 
restricted feeding conditions from the left ventricle of 
the heart. A relevant flow diagram presenting the study 
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design together with the experimental approach and 
multi-dimensional data analysis is shown in Fig. 1.
All procedures involving animals were conducted 
according to the ‘Guide for the Care and Use of the Labo-
ratory Animals’ published by the European Parliament, 
Directive 2010/63/EU and were approved by the local 
Ethical Committees at the Medical University of Gdansk 
and the University of Agriculture in Krakow.
Proteomic analysis of plasma
Plasma samples collected from knockout (n = 6) and 
control (n = 6) mice were pre-treated with an Aurum™ 
Serum Protein Mini Kit (Bio-Rad Laboratories, CA, 
USA) according to the manufacturer’s instructions. Pro-
teins obtained by this enrichment method were subjected 
to a standard procedure of in-solution tryptic digestion 
followed by quantitative proteomics experiments using a 
well-validated label-free MS-based method [29–31].
The resulting peptide mixtures were applied onto an 
RP-C18 trapping column (20 mm × 180 µm, 5 µm; Waters, 
Milford, USA) of the nanoUPLC system using 0.1% (v/v) 
formic acid in water as the mobile phase and then trans-
ferred to a nanoACQUITY UPLC BEH  C18 analytical 
column (250 mm × 75 µm, 1.7 µm; Waters, USA) using a 
160-min linear gradient of 0–35% acetonitrile (ACN) at a 
flow rate of 250 nL/min. The column outlet was directly 
coupled to the nanoelectrospray (nanoESI) ion source 
of the LTQ-Orbitrap Velos mass spectrometer (Thermo 
Scientific, San Jose, USA). Each sample was measured in 
duplicate—once for protein sequencing (data-dependent 
MS to MS/MS switch) and once for quantitative infor-
mation (MS only, sequencing disabled). Full MS spec-
tra were collected at a resolution of 60,000 (for ions at 
m/z 400) over the range of m/z 300–2000. The ten most 
abundant precursor ions were selected for fragmenta-
tion, which was achieved using higher-energy collisional 
dissociation (HCD) with a normalized collision energy 
setting of 35%. The MS/MS spectra were collected at 
a resolution of 15,000 (m/z 400) and parent ion activa-
tion was performed with an isolation width of 2 Da and a 
minimal intensity of 5,000 counts. Further details regard-
ing the analytical conditions that were applied can be 
found in [29, 30].
The acquired MS/MS data were pre-processed with 
Mascot Distiller software (v. 2.3, Matrix Science, Lon-
don, UK), and the search was carried out with the Mas-
cot Search Engine (Matrix Science, Mascot Server 2.4) in 
a three-step procedure described elsewhere [29] against 
the set of Mus Musculus protein sequences derived from 
the Uniprot database (total 74,459 proteins), merged 
with a randomized version. The initial search param-
eters were set as follows: 20 ppm tolerance for precursor 
ion masses; 0.4 Da for fragment ion masses; a maximum 
of two missed tryptic cleavages; fixed modification: 
Fig. 1 A flow diagram of multi‑omic analysis was used to present the overview of the study design, how the experiments were performed, as well 
as the way of data treatment
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carbamidomethylation (C); variable modifications: oxi-
dation (M), acetyl (peptide N-term) and deamidation (N, 
Q). A statistical assessment of peptide assignments was 
built on the concatenated target/decoy database search 
strategy and a procedure that provided the q-values for 
each peptide spectrum match (PSM). Only PSMs with 
q-values of ≤ 0.01 and proteins represented by at least 
two peptides were regarded as confidently identified. 
The list of peptides meeting the aforementioned accept-
ance criteria and unique for proteins’ identification were 
subjected to a step of quantitative analysis to obtain a 
list of proteins differentially expressed between a set 
of  ApoE−/−/LDLR−/− and WT mice. A more detailed 
description of the MS-based proteomic procedures is 
available in our previous work [31].
Confirmation of plasma protein variations by ELISA 
analysis
Immunoassays-based quantitations of serum amyloid 
A-1 protein (SAA1), proprotein convertase subtilisin/
kexin type 9 (PCSK9), soluble vascular cell adhesion mol-
ecule-1 (sVCAM-1), fibrinogen (FBG), angiotensinogen 
(AGT) and glutathione peroxidase 3 (GPx-3) were all 
performed using commercial kits according to the manu-
facturer’s protocols (Abcam, Cambridge, UK). Of note, 
alterations in AGT level were evaluated because results 
from untargeted runs indicated that the expression of 
enzymes responsible for its degradation/conversion was 
largely up-regulated, suggesting massive over-activation 
of RAS.
Metabolomic analysis of plasma
Metabolomic profiling of plasma was performed accord-
ing to the protocol described previously [31]. Briefly, 
aliquots of 50 µL of plasma samples were pipetted into 
2-mL vials, followed by the addition of 10 μL of the inter-
nal standard solution and ACN at the proportion of 2:1 
(v/v) into each vial. The tubes were then centrifuged at 
4 °C, 16,000×g for 15 min, and the resultant supernatant 
was collected and subjected to freeze-drying. The residue 
was next reconstituted with 50 μL of 0.1% formic acid 
in water and analysed using an LC–MS/MS system as 
detailed below.
Simultaneous determination of 44 underivatized amino 
acids (AAs) in mouse plasma was performed using a Sur-
veyor HPLC system (Thermo Scientific, San Jose, CA, 
USA) coupled to a TSQ Vantage Triple-Stage Quadru-
pole mass spectrometer (Thermo Scientific) that was 
equipped with a heated electrospray ionization probe 
(HESI-II). The chromatographic separation was achieved 
on a Synergi Hydro-RP column (50  mm × 2.0  mm, 
2.5  µm; Phenomenex, Torrance, CA, USA) maintained 
at 25 °C. The mobile phase consisted of deionized water 
(A) and ACN (B), containing 5  mM nonafluoro-1-pen-
tanoic acid (to improve the retention of polar analytes, 
A) and 0.1% formic acid (B), respectively, and the elu-
tion gradient used was as follows: 0  min, 0% B; 2  min, 
30% B; 4.5  min, 45% B; 4.5–9  min 0% B, resulting in a 
total run time of 9  min. The flow rate was 0.2  mL/min, 
and the injection volume was 2 µL. Data acquisition was 
carried out in selected reaction monitoring (SRM) mode 
employing electrospray ionization (ESI) in positive mode. 
Analytical method details, as well as the MS/MS transi-
tions monitored in the protocol, are described elsewhere 
[31]. Instrument control, data collection and analysis 
were achieved using Thermo Xcalibur 2.1 software.
Systemic and tissue angiotensin (Ang) profile 
determination
Circulating and aortic Ang peptide concentrations were 
determined by mass spectrometry linked to liquid chro-
matography using plasma/tissue samples collected in the 
presence of a protease inhibitor cocktail that completely 
blocked Ang metabolism, as described previously [32]. 
Stabilized protease inhibitor samples (25 µL) were fur-
ther spiked with 5 µL internal standard solution  ([Asn1, 
 Val5]-Ang II) at a concentration of 250 pg/mL and depro-
teinized with ACN (in 4:1 (v/v) proportion to the sam-
ples used). Following C18-based solid-phase-extraction, 
samples were subjected to LC–MS/MS analysis using a 
reversed-phase analytical column (Acclaim PepMap100 
RSLC C18, 150 mm × 75 µm, 2 µm) of the UltiMate 3000 
Rapid Separation nanoLC system operating in line with 
a TSQ Vantage triple quadrupole mass spectrometer 
(Thermo Scientific). Separation of the peptides was per-
formed by gradient elution using a mobile phase com-
prising water (solvent A) and ACN (solvent B), both 
containing 1% acetic acid (v/v). The flow rate was 300 nL/
min, and the overall chromatographic run time including 
re-equilibration was 50  min. For the MS detection, the 
instrument was operated in the positive ESI mode, and 
the acquisition was performed in SRM mode. The two 
most sensitive/specific ion transitions were measured for 
each of the nine Ang peptides determined [Ang-(1–12), 
Ang I, II, III, IV, (1–7), (1–9), Ang A and alamandine]. 
Optimum analytical conditions, as well as the precursor 
and product ions used in the protocol, were described 
previously [32]. The instrumental operation, data acquisi-
tion and peak integration were performed using Thermo 
Xcalibur 2.1 software.
Familial hypercholesterolemia patients and controls
Serum samples of patients with FH diagnosed both clini-
cally and genetically (under the care of the National Cen-
tre for Familial Hypercholesterolemia in Gdansk) and 
non-FH normolipidemic subjects as controls were used 
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in this study. FH cases and controls were divided into dis-
covery (n = 20 + 20) and validation (n = 29 + 29) cohorts. 
The participation of the study subjects was approved by 
the Bioethics Committee at the Medical University of 
Gdansk upon written informed consent. All procedures 
involving human participants were in accordance with 
the ethical standards of the 1964 Helsinki declaration and 
its later amendments. FH patients and healthy control 
subjects were matched for age, sex and body mass index 
(BMI). Subjects’ clinical characteristics are compiled in 
Additional file 1: Tables S4 and S5.
Analysis of protein and metabolite signatures in human 
sera
Serum concentrations of candidate proteins: C-reactive 
protein (CRP), PCSK9, apolipoprotein C-III (ApoC-III), 
soluble intercellular adhesion molecule-1 (sICAM-1), 
AGT, paraoxonase/arylesterase 1 (PON-1), fetuin-B 
(FETUB), vitamin K-dependent protein S (VKDP-S) and 
biglycan (BGN) (Abcam, Cambridge, UK; Uscn, Life Sci-
ence Inc. USA) were determined in individual controls 
and patient subjects using ELISA kits according to the 
manufacturer’s protocols.
For metabolite analysis, serum protein removal was 
performed by precipitation in pre-chilled ACN, and the 
resultant supernatant was collected and subjected to 
freeze-drying. After reconstitution in 0.1% formic acid in 
Milli-Q water, samples were analysed by (SRM)-LC‐MS/
MS as described in the previous paragraph.
Statistical and pathway analyses
Data are presented as mean ± SEM unless otherwise 
noted. Statistical differences were determined using 
Student’s unpaired t test (when two groups were com-
pared) or one-way ANOVA with a Bonferroni post hoc 
test (when more than two groups were compared). Com-
parisons resulting in p-values lower than 0.05 were con-
sidered statistically significant. Statistical analyses were 
performed using Prism 9.0 (GraphPad Software, Inc., La 
Jolla, CA, USA).
Protein–protein interaction analysis of the differen-
tially expressed proteins was performed using STRING 
11.0 software with the following analysis parameters: 
species—Mus musculus, confidence level − 0.4 and active 
prediction methods-all. This freely available database 
of known and predicted protein interactions provides 
information on associations derived from genomics, 
high-throughput experiments, co-expression and pre-
vious knowledge. Metabolic pathway analysis (MetPA) 
was performed using MetaboAnalyst 4.0 (http://www.
metab oanal yst.ca/) to identify potentially affected meta-
bolic pathways. This web tool conducts pathway analysis 
through pathway enrichment and topological analysis. In 
this study, we selected the Mus musculus library and used 
the default ‘Hypergeometric Test’ (for pathway enrich-
ment analysis) and the ‘Relative-Betweenness Centrality’ 
algorithm (for pathway topological analysis). To identify 
the most relevant pathways, the impact-value threshold 
derived from pathway topology analysis was set to 0.1. 
A multivariate ROC (Receiver Operating Characteristic) 
curve based exploratory analysis was performed for the 
purpose of the most discriminative features’ selection, 
model building, and performance evaluation and that was 
achieved with MetaboAnalyst 4.0 web server (Biomarker 
Analysis module). The Random Forest for the classifica-
tion and “Random Forest built-in” for the feature rank-
ing method was employed as a multivariate algorithm to 
facilitate in selecting variables with the highest predic-
tive accuracy. The survival rates among groups were esti-
mated by the Kaplan–Meier method and compared using 
a log-rank test.
Results
Protein alterations in response to atherogenic 
dyslipidaemia
We first investigated the most significant protein changes 
in plasma of dyslipidaemic mice. Hence, differential pro-
tein expression analysis with LC/MS was performed 
using 6 specimens per group matched by age, gender 
and basal characteristics. Of a total of 523 unique pro-
teins identified with a sufficient MS signal in the current 
study, 279 were detected in at least 4 samples per group, 
which constituted our threshold for inclusion in the sta-
tistical analysis (dataset provided in attached Additional 
file 2). Statistical analysis of the data revealed changes in 
the abundance of 47 proteins (q < 0.05): 34 up-regulated 
and 13 down-regulated in atherogenic dyslipidaemia 
(Table  1). The majority of these differentially expressed 
proteins could be classified into relevant functional cat-
egories, namely: (1) inflammation and immune response 
(serum amyloid A-1/A-2/A-3/A-4 protein, serum amy-
loid P-component, α-2-macroglobulin, α-1-antitrypsin 
1-1/1-2/1-3, adiponectin, gelsolin, complement com-
ponent C9, complement factor B, complement factor 
H, inter alpha-trypsin inhibitor, heavy chain 4), (2) lipid 
transport/metabolism (apolipoprotein A-IV, apolipo-
protein B-100, apolipoprotein C-I, apolipoprotein C-III, 
proprotein convertase subtilisin/kexin type 9), (3) adhe-
sion of leukocytes to endothelial cells (ECs)/endothe-
lial activation (vascular cell adhesion protein 1, laminin 
subunit gamma-1, thrombospondin-4, angiopoietin-1), 
(4) blood coagulation/fibrinolysis (von Willebrand fac-
tor, coagulation factor VII, vitamin K-dependent protein 
S, fibrinogen beta chain, kininogen-1, plasma kallikrein), 
(5) RAS (renin-angiotensin system) over-activation 
(angiotensin-converting enzyme (ACE), cathepsin D), 
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Table 1 Most significant proteins differentially expressed in plasma of   ApoE−/−/LDLR−/− vs. wild-type mice as revealed 
by proteomic analysis (the ratio is given as  ApoE−/−/LDLR−/−/control)
No UniProtKB ID/
Accession number
Q value Ratio Peptide count Protein annotation
(Short name)
Involvement in the biological process
1 P15535 N/A* Only in  2# 2 Beta‑1,4‑galactosyltransferase 1
(Beta‑1,4‑GalTase 1)
Protein glycosylation
2 P07310 N/A Only in  1# 2 Creatine kinase M‑type (M‑CK) Energy transduction/Creatine metabolism
3 P29533 N/A Only in 1 2 Vascular cell adhesion protein 1 
(VCAM‑1)
Leukocyte‑endothelial cell adhesion
4 P02468 N/A Only in 1 2 Laminin subunit gamma‑1 (S‑LAM 
gamma)
Cell adhesion
5 P24270 N/A Only in 2 2 Catalase (Cat) Detoxification of Reactive Oxygen Species
6 O89023 N/A Only in 1 2 Tripeptidyl‑peptidase 1 (TPP‑1) Peptide catabolic process/Vessels wall injury
7 P63017 N/A Only in 1 2 Heat shock cognate 71 kDa protein 
(Hspa8)
Molecular chaperone implicated in a wide 
variety of cellular processes associated with 
proteome organization
8 P04918 N/A Only in 1 5 Serum amyloid A‑3 protein (SAA3) Acute‑phase response
9 P06728 0.00003 0.57 64 Apolipoprotein A‑IV (ApoA‑IV) Lipid transport/metabolism
10 P13020 0.00003 0.00003 31 Gelsolin (GSN) A key component of the innate immune 
system
11 E9Q414 0.00003 1.44 339 Apolipoprotein B‑100 (ApoB‑100) Lipid transport/metabolism
12 P05366 0.00003 3.13 11 Serum amyloid A‑1 protein (SAA1) Acute‑phase response
13 P05367 0.00003 3.34 15 Serum amyloid A‑2 protein (SAA2) Acute‑phase response
14 A6X935 0.00003 1.38 72 Inter alpha‑trypsin inhibitor, heavy 
chain 4 (ITI‑HC4)
Acute‑phase response/Hyaluronan metabolic 
process
15 Q61838 0.00073 0.82 81 Alpha‑2‑macroglobulin (Alpha‑2‑M) Disruption of inflammatory cascade/Serine 
protease inhibition
16 Q921I1 0.00077 0.43 23 Serotransferrin (Transferrin/STF) Iron transport
17 P07309 0.00082 0.71 9 Transthyretin (TTR) Retinoid metabolism and transport
18 P12246 0.00367 2.55 10 Serum amyloid P‑component (SAP) Acute‑phase response
19 P06683 0.00377 1.44 17 Complement component C9 (C9) Complement alternate pathway
20 Q91X72 0.00489 0.58 22 Hemopexin (HPX) Scavenging of heme from plasma
21 P31532 0.01109 21.671 14 Serum amyloid A‑4 protein (SAA4) Acute‑phase response
22 P07758 0.01969 1.46 14 Alpha‑1‑antitrypsin 1‑1 (Serpina 1a) Acute‑phase response
23 Q00896 0.01969 1.39 14 Alpha‑1‑antitrypsin 1‑3 (Serpina 1c) Acute‑phase response
24 P04186 0.02333 1.35 17 Complement factor B (CFB) Complement alternate pathway
25 P22599 0.03604 1.44 6 Alpha‑1‑antitrypsin 1‑2 (Serpina 1b) Acute‑phase response
26 Q80W65 0.03649 1.83 11 Proprotein convertase subtilisin/
kexin type 9 (PCSK9)
Cholesterol metabolism
27 Q8BPB5 0.03766 0.73 7 EGF‑containing fibulin‑like extracel‑
lular matrix protein 1 (FIBL‑3)
A growth factor in the arteries
28 P51885 0.03795 1.58 17 Lumican (LUM) Collagen fibril organization
29 P06909 0.03892 1.31 23 Complement factor H (CFH) Complement alternate pathway
30 P28653 0.03905 1.95 13 Biglycan (BGN) Blood vessel remodelling
31 Q60994Q60994 0.039430.03943 0.45 6 Adiponectin (AdipoQ/APN) Negative regulation of tumor necrosis factor‑
mediated signaling pathway
32 P70375 0.04003 1.55 9 Coagulation factor VII (FVII) Blood coagulation
33 Q08761 0.04005 0.79 12 Vitamin K‑dependent protein S 
(VKDP‑S)
Prevention of coagulation/Fibrinolysis 
stimulation
34 Q9Z1T2 0.04106 1.47 2 Thrombospondin‑4 (TSP‑4) Endothelial cell–cell adhesion/Tissue remodel-
ling
35 Q8K0E8 0.04213 1.62 10 Fibrinogen beta chain (FGB) Blood coagulation
36 Q9QXC1 0.04378 1.54 4 Fetuin‑B (FETUB) Regulation of vascular plaque‑stabilizing 
factors
37 O08677 0.04451 1.29 19 Kininogen‑1 (KNG1) Blood coagulation
38 P09470 0.04568 1.66 28 Angiotensin‑converting enzyme 
(ACE)
Angiotensin II generation/Bradykinin inactiva-
tion
39 P26262 0.04571 1.48 11 Plasma kallikrein (pKal) Blood coagulation/Inflammatory response
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* N/A – not applicable; # only in 1 refers to ApoE/LDLR−/−, whereas in 2 refers to controls
& These proteins were involved in the table (despite q-value slightly higher than 0.05) as they support biological conclusion about profoundly affected anti-oxidative 




Q value Ratio Peptide count Protein annotation
(Short name)
Involvement in the biological process
40 O08538 0.04864 1.62 8 Angiopoietin‑1 (ANG‑1) Regulation of blood vessel endothelial cell 
migration/cell adhesion/monocyte recruit-
ment and retention
41 Q8CIZ8 0.04903 1.83 19 Von Willebrand factor (vWF) Blood coagulation/Cell adhesion/Platelet 
activation
42 P34928 0.049540.04954 1.54 7 Apolipoprotein C‑I (ApoC‑I) Lipid transport/metabolism
43 P18242 0.04966 1.38 4 Cathepsin D (Cath‑D) Cleavage of angiotensinogen to produce 
angiotensin I/Renin‑like activity
44 P33622 0.04986 1.47 8 Apolipoprotein C‑III (ApoC‑III) Lipid transport/metabolism
45 P04202 0.04997 1.44 8 Transforming growth factor beta‑1 
(TGF‑beta‑1)
Controlling of proliferation, differentiation and 
cell migration/Induction of epithelial‑to‑
mesenchymal transition
&46 P52430 0.05003 0.58 25 Serum paraoxonase/arylesterase 1 
(PON‑1)
Enzymatic protection of low‑density lipopro-
teins against oxidative modification
&47 P46412 0.05015 0.72 10 Glutathione peroxidase 3 (GPx‑3) Detoxification of Reactive Oxygen Species
Fig. 2 The protein–protein interactions for the differentially expressed proteins in  ApoE−/−/LDLR−/− mice (vs. WT) that were analysed using 
STRING 11 software. In the network analysis the differentially expressed proteins were presented as nodes, whereas edges represent predicted 
protein–protein associations. Using the protein interaction network analysis tool (STRING database), seven networks of the associated proteins 
were found among the differentially expressed proteins that were depicted by relevant colours. These included proteins mainly involved in: (1) 
acute phase response and/or being a constituent of lipoprotein particles (olive), (2) coagulation cascade (red), (3) alternative complement pathway 
(mint), (4) existing as inhibitors of serine proteases (light blue), (5) participating in adhesion of leukocytes to endothelial cells/renin‑angiotensin 
system over‑activation or modulation of oxidative stress (turquoise), (6) modulation of extracellular interactions/extracellular matrix re‑organization 
(salmon), and (7) others – the disconnected node in the network represented by creatine kinase (hidden in the plot)
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(6) detoxification of reactive oxygen species (ROS) (cata-
lase, serum paraoxonase-1, glutathione peroxidase 3), 
(7) extracellular matrix reorganization/arterial remodel-
ling (tripeptidyl-peptidase 1, EGF-containing fibulin-like 
extracellular matrix protein 1, lumican, biglycan, fetuin-
B, transforming growth factor beta-1), and (8) haeme 
clearance (hemopexin, serotransferrin).
To better understand the nature of the differentially 
expressed proteins and how these proteins interact 
with each other, we searched the String database for 
known and predicted protein associations against the 
proteins we identified. Figure  2 presents constructed 
protein–protein interaction networks. Further, to vali-
date the results obtained by the label-free MS-based 
method, six representative proteins (SAA1, PCSK9, 
sVCAM-1, FBG, AGT and GPx-3) reflecting the diverse 
nature of biochemical processes in which they par-
ticipated were selected for immunochemical analy-
ses. In these analyses, SAA1, PCSK9, sVCAM-1, FBG 
and AGT were found to be up-regulated in plasma of 
 ApoE−/−/LDLR−/− mice (vs WT), whereas GPx-3 was 
down-regulated, which is consistent with the results 
obtained from the non-targeted proteomics approach 
(Additional file 1: Figure S1).
Metabolic alterations in response to atherogenic 
dyslipidaemia
To investigate the metabolic changes that occurred in 
plasma in response to atherogenic dyslipidaemia, plasma 
samples  (ApoE−/−/LDLR−/− and WT) were explored 
by targeted LC–MS/MS. A total of 44 compounds were 
quantified (Additional file  1: Table  S6), among which 
amino group-containing metabolites represented the 
most important subset of the metabolome. These metab-
olites included proteinogenic and non-proteinogenic 
amino acids carrying amino and acidic (e.g., carboxyl 
or sulfonic) groups, post-translationally modified (e.g., 
methylated) amino acids, small peptides, thiol and disul-
phide containing amino metabolites. Because they cover 
dozens of important metabolic pathways, quantitative 
analysis of these metabolites is, therefore, critical for bio-
marker discoveries. Twenty-four metabolites were signif-
icantly altered (p-value < 0.05) in  ApoE−/−/LDLR−/− mice 
compared with the wild types. Among these metabolites, 
the plasma levels of 6 metabolites, asymmetric (ADMA) 
and symmetric (SDMA) dimethylarginines, homocyst-
eine (Hcy), 1-methylnicotinamide (MNA), 5-hydrox-
ylysine (Hyl) and 4-hydroxyproline (Hyp) increased 
strikingly in dyslipidaemic mice compared with the 
controls, whereas the levels of 3 other (alanine (Ala), 
creatinine (Cre) and monomethylarginine (NMMA)) 
metabolites accumulated markedly. In contrast, urea 
cycle-related AAs (i.e., arginine (Arg), citrulline (Cit), 
ornithine (Orn) and glutamine (Gln)) and branched-
chain AA (BCAA)-related AAs (isoleucine (Ile), leucine 
(Leu)), as well as taurine (Tau) and methionine (Met), 
were down-regulated in pathological samples. In addi-
tion, the plasma L-Arg/ADMA ratio and homoarginine 
(H-Arg) concentration—the indicators for NO bioavail-
ability—were decreased with atherogenic dyslipidaemia. 
A total of 15 metabolites with the most altered plasma 
features were selected and are presented in Fig. 3. Meta-
bolic pathway analysis revealed nine pathways involved 
in response to dyslipidaemia (Fig. 4).
Systemic and local RAS alterations in  ApoE−/−/LDLR−/− 
mice
We compared the plasma and aortic levels of nine Ang 
peptides in the pathological and normal state (Additional 
file 1: Figure S2). Circulating levels of Ang I and Ang II, as 
well as other pathological effectors of the RAS (Ang III, 
IV, A), were significantly elevated in dyslipidaemic mice 
compared with the wild types, whereas the increase in 
Ang-(1–12) was modest. These changes were associated 
with a decrease in plasma Ang-(1–7) concentration and 
Ang-(1–7)/Ang II ratio (in  ApoE−/−/LDLR−/− mice). In 
the aorta, the pattern of changes was largely convergent 
with that observed in plasma, pointing to an over-acti-
vation of the ACE/Ang II pathway and down-regulation 
of the ACE-2/Ang-(1–7) pathway. Interestingly, the low 
levels of Ang-(1–10) at relatively high Ang-(1–12) could 
suggest the existence of an alternative pathway of Ang 
II generation that may be dependent on chymase in the 
aorta.
Effect of pro‑atherogenic diets on plasma AA metabolome
Dietary treatments (LCHP (low-carbohydrate, high-
protein) or Western diet) promoted atherosclerosis in 
 ApoE−/−/LDLR−/− mice (Additional file  1: Fig. S3) [33] 
and had a significant impact on plasma metabolomic 
pattern (Additional file  1: Table  S7). LCHP diet accel-
erated the disease more intensively than the classical 
Western diet and favoured the development of unstable 
lesions (Additional file 1: Fig. S3) [33, 34] that translated 
into more profound metabolic alterations as compared 
with WD. The plasma levels of metabolites that initially 
were significantly elevated in pathological samples (i.e., 
ADMA, SDMA, Hcy, MNA, Hyp, Ala) further increased 
with WD or LCHP feeding. A massive increase in the 
concentration of dimethylarginines and MNA was a 
dominant feature of the plasma metabolite profile of ani-
mals fed the LCHP diet as compared to other (AIN-93G 
or Western) diets. Surprisingly, the increase in MNA was 
as much as fourfold in LCHP-fed  ApoE−/−/LDLR−/− in 
comparison to mice fed the control diet. By contrast, 
the levels of urea cycle-related AAs, as well as Met and 




Fig. 3 Significantly altered metabolites in response to atherogenic dyslipidaemia in  ApoE−/−/LDLR−/− mice. Plasma concentration of substrates 
for NOSs (L‑Arg, H‑Arg) and Arg precursors (L‑Cit, L‑Orn) (a), methylated Arg derivatives (NMMA, SDMA, ADMA) as well as L‑Arg/ADMA ratio (b), 
L‑Met, Hcy (c) and other metabolites significantly changed in response to dyslipidaemia (d) in  ApoE−/−/LDLR−/− (n = 7) and WT (n = 9) mice. Data 
represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. WT
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Tau, were diminished with LCHP feeding. Interestingly, 
plasma creatinine concentration significantly decreased 
in  ApoE−/−/LDLR−/− on atherogenic diets; this result 
may indicate a compensatory increase in creatinine clear-
ance in these animals. Figure 5 presents the top 15 most 
important metabolite features identified.
Translational study in patients with familial 
hypercholesterolemia
To translate our pre-clinical findings into a human set-
ting, we also characterized molecular alterations in 
human serum samples. A distinct set of proteins for 
comparison was selected based on initial conclusions 
received for animal samples that were subjected to com-
parative global blood plasma protein profiling. Only 
some minor changes (in the pattern of proteins’ deter-
mined) were implemented based on the literature or our 
previous observations: (1) sVCAM-1 was replaced by 
sICAM-1 because the latter proved to be more up-reg-
ulated in humans in response to hyperlipidaemia [35], 
(2) CRP level (instead of SAA) was analysed since it is 
more commonly used in clinical practice demonstrat-
ing comparable sensitivity as a measure of inflammation 
[36] and, finally, (3) alterations in AGT level were evalu-
ated to verify whether dyslipidaemia also initiated pro-
found RAS activation in human samples. Nine proteins 
(PCSK9, ApoC-III, sICAM-1, AGT, PON-1, FETUB, 
VKDP-S, BGN and CRP) were found significantly altered 
in sera from FH patients as compared to the healthy sub-
jects (Fig.  6). CRP, PCSK9, ApoC-III, sICAM-1, AGT, 
Val, Leu, Ile catabolism
Phe, Tyr, Trp biosynthesis
Tau, Hypotau metabolism
Arg, Pro metabolism





Fig. 4 Summary of altered metabolic pathways analysed by MetaboAnalyst 4.0 web software. As shown, nine metabolic pathways of importance 
were disturbed in the plasma of dyslipidaemic mice (as compared to the wild‑types): (1) valine, leucine and isoleucine degradation; (2) 
phenylalanine, tyrosine and tryptophan biosynthesis; (3) taurine and hypotaurine metabolism; (4) arginine and proline metabolism; (5) alanine, 
aspartate and glutamate metabolism; (6) tryptophan metabolism; (7) nicotinate and nicotinamide metabolism; (8) tyrosine metabolism, and (9) 
cysteine and methionine metabolism. Significantly affected pathways are plotted according to P‑value from pathway enrichment analysis and 
pathway impact score from pathway topology analysis. Circle size and colour gradient indicate the significance of the pathway ranked by P‑value 
(red: lower P‑values and yellow: higher P‑values) and pathway impact score (the larger the circle the higher the impact score), respectively
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FETUB and BGN were up-regulated in pathological 
human samples, presenting the same trend observed in 
 ApoE−/−/LDLR−/− plasma samples. In turn, PON-1 and 
VKDP-S were found down-regulated in FH sera, similar 
to the animal plasma samples, although variations in the 
concentration of the latter were minor. Further, a total of 
24 metabolites were found significantly altered in human 
sera, highly similar to the trend observed in animal sam-
ples (Additional file 1: Table S8). Compared with the nor-
molipidemic subjects, FH patients had remarkably higher 
Hcy, Ala as well as methylated Arg concentrations, but 
they also had lower levels of BCAAs and AAs engaged 
in NO generation. In contrast, among the dimethylated 
Args determined, the level of SDMA was substantially 
more elevated than ADMA in hyperlipidaemic subjects 
and  ApoE−/−/LDLR−/− plasma samples as compared to 
 ApoE−/−/LDLR−/− on atherogenic diets, where a massive 
increase in ADMA was observed that clearly illustrates 
that SDMA, rather than ADMA, might be a suitable 
marker of early atherosclerotic disease before the devel-
opment of a lumen-compromising plaque. Gln and Tau, 
with potent anti-inflammatory/antioxidant properties, 
were also significantly down-regulated in FH sera, poten-
tially suggesting the dysregulation of defences against 
oxidative stress. By contrast, MNA concentration was 
only slightly elevated in comparison to the strikingly high 
increase observed in  ApoE−/−/LDLR−/− plasma sam-
ples. Similarly, only a mild increase in Hyp (the elevated 
plasma level of which has been recognized as a possi-
ble risk factor associated with connective tissue injuries 
[37]) was identified in hyperlipidaemic patient samples 
vs normolipidemic samples. Most of these metabolomic 
alterations can be found in Fig. 7. Interestingly, the treat-
ment of FH patients with cholesterol-lowering drugs 
(statins) normalized molecular disturbances induced 
by dyslipidaemia (Figs.  6, 7). Hence, to corroborate the 
discriminative potential of the molecules described 
above, further investigation was carried out on an addi-
tional cohort of cases (Additional file  1: Table  S5). That 
study demonstrated a largely overlapped pattern of dys-
regulated metabolites/proteins when these two clini-
cal cohorts were compared with each other (Additional 
file 1: Figures S4, S5, Table S9), thus confirming the value 
of a molecular signature that was ascribed to atherogenic 
dyslipidaemia.
The essential proteins and metabolites that differen-
tiated the two groups studied were further classified 
according to their most important biological functions in 
9 groups: (1) inflammation and immune response (CRP, 
Gln), (2) lipid transport/metabolism (PCSK9, ApoC-III, 
Leu), (3) NO generation (Arg, Cit, Orn, H-Arg, NMMA, 
SDMA, ADMA, Met, Hcy), (4) adhesion of leukocytes to 
ECs/endothelial activation (sICAM-1), (5) blood coagu-
lation/fibrinolysis (VKDP-S, MNA), (6) RAS over-activa-
tion (AGT), (7) detoxification of ROS (PON-1, Tau), (8) 
extracellular matrix reorganization/arterial remodelling 
(BGN, FETUB, Hyp) and (9) response to ischemia (Ala). 
Subsequently, the performance of these molecules in 
responding to atherogenic dyslipidaemia was evaluated 
by calculating the ROC curves of multiple features com-
bined. The model that entered only 10 features (out of the 
25 studied) exhibited area under the ROC curve value 
over 99% thus confirming its high predictive accuracy – 
the observation noted in the primary as well as validation 
cohorts (Fig. 8).
Discussion
This study applied an integrated ‘–omic’ approach to 
characterize the main alterations, both at protein/peptide 
and metabolite levels, associated with dyslipidaemia and 
development of atherosclerosis. Although several similar 
approaches have been proposed to study the pathogen-
esis of the disease, they suffer from limited applicability 
to humans as these studies have been conducted only in 
pre-clinical settings, with a single ‘omics’ technology pro-
viding a limited view of the molecules dysregulated or 
on a limited number of specimens, making it difficult to 
draw general conclusions [22, 24–26]. To the best of our 
knowledge, this is the first time that such a large, compre-
hensive multi-omic approach has been employed for the 
study of atherosclerosis in both experimental and clini-
cal (on two patient cohorts) settings, and thanks to this 
design, we hereby describe an original panel of proteins 
and metabolites corresponding to dyslipidaemia-induced 
atherosclerosis.
Accumulation and retention of low‑density lipoproteins 
(LDLs) in the arterial intima and their oxidative 
modification
According to the ‘response-to-retention’ hypoth-
esis of atherogenesis, retention of apolipoprotein 
Fig. 5 Effect of pro‑atherogenic diets (Western and low‑carbohydrate, high‑protein (LCHP) diets) on plasma AA (amino acid‑related) metabolome 
in  ApoE−/−/LDLR−/− mice. Plasma concentration of substrates for NOSs (L‑Arg, H‑Arg) and Arg precursors (L‑Cit, L‑Orn) (a), methylated Arg 
derivatives (NMMA, SDMA, ADMA) as well as L‑Arg/ADMA ratio (b), L‑Met, Hcy (c) and other metabolites related to atherosclerosis progression (d) 
in 6‑month‑old  ApoE−/−/LDLR−/− mice fed for 2 months: Control‑AIN‑93G (n = 6), WD (n = 5) or LCHP (n = 5) diet, respectively. Data represent 
mean ± SEM. *, **, and *** indicate P < 0.05, P < 0.01, P < 0.001, respectively
(See figure on next page.)
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Fig. 6 Translational study in human sera coming from patients affected by FH (n = 20) and healthy subjects (n = 20) (discovery cohort). 
Quantification of selected marker candidates (CRP, PCSK9, ApoC‑III, sICAM‑1, AGT, PON‑1, FETUB, VKDP‑S, and BGN) in crude serum samples by 
colorimetric ELISA. Protein levels are presented as mean ± SEM. *, **, and *** indicate P < 0.05, P < 0.01, P < 0.001, respectively. FH + S – FH patients 
receiving statin therapy
Fig. 7 A snapshot of serum metabolites in the setting of familial hypercholesterolemia (discovery cohort). Human metabolomic signatures related 
to atherogenic dyslipidaemia closely reflect the pattern already identified in  ApoE−/−/LDLR−/− mice. The top (a) row depicts serum concentration 
of substrates for NOSs (L‑Arg, H‑Arg) and Arg precursors (L‑Cit, L‑Orn), the middle rows ‑methylated Arg derivatives (NMMA, SDMA, ADMA) and 
L‑Arg/ADMA ratio (b), and L‑Met, Hcy (c), respectively and d refers to other altered metabolites determined in FH cases (n = 20) vs. healthy subjects 
(n = 20). Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. FH + S – FH patients on statins
(See figure on next page.)
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Fig. 8 Receiver operating characteristic (ROC) curves (a–d), showing the ability of the potential biomarkers to distinguish between control subjects 
and FH patients, as well as heatmaps data visualization to depict variance across multiple variables (e, f). a, b Multivariate ROC curves of the six 
models in primary and validation cohorts have been generated employing random forest prediction model with combined features. We found that 
the model with 10 features entered showed excellent predictive performance with ROC AUC (area under the curve) values > 99% for both discovery 
and validation data. c, d 15 significant features were ranked based on their average importance (in group classification) during cross validation. e, f 
Color‑coded maps that illustrate the relative abundance of feature combinations for two independent cohorts of cases
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B/E-containing lipoproteins within the vessel wall is nec-
essary for initiating an atherogenesis event [38]. In par-
ticular, proteoglycans with elongated glycosaminoglycan 
chains, including biglycan (BGN), perlecan and decorin 
seem to play a crucial role in this process [38, 39]. Posi-
tively charged structures on apolipoproteins can ionically 
interact with negatively charged sulphate and carboxylic 
acid groups on glycosaminoglycans, leading to prolonged 
retention of atherogenic lipoproteins in the subendothe-
lial space. Furthermore, co-localization studies have 
demonstrated that in humans, BGN is a key proteoglycan 
mediating lipid retention, whereas in mice, both BGN 
and perlecan co-localize with apolipoproteins [40, 41]. 
This observation is consistent with our results showing 
BGN to be significantly up-regulated under pathological 
conditions, both in animals and humans. However, the 
particular role of BGN in atherosclerosis development 
has yet to be well defined; Tang et al. [42] have recently 
demonstrated that over-expression of BGN increased 
atherosclerosis, but BGN deficiency was not protective. 
On the other hand, increased vascular perlecan content 
in BGN-deficient mice (observed in these studies) might 
suggest a compensatory response of the vasculature for 
the BGN deficiency. Other potential effects of BGN, 
including its role in inflammation, regulation of growth 
factor availability and involvement in thrombin genera-
tion require further elucidation [43].
Interestingly, ApoC-III has been shown to increase the 
binding of LDLs to artery wall proteoglycans, although 
this increase was not related to its direct binding by itself 
[44]. In our studies, elevated plasma/serum ApoC-III 
concentration was one of the most characteristic features 
in pathologically changed samples and supports previ-
ous observations suggesting its critical role in promot-
ing atherosclerosis and other metabolic diseases [45, 46]. 
Although ApoC-III atherogenicity was primarily attrib-
uted to hypertriglyceridemia [47] because of its ability to 
inhibit endothelial-bound lipoprotein lipase, recent evi-
dence expands this function and reveals ApoC-III’s key 
role in endothelial activation and arterial inflammation 
[44]. Kawakami et al. [48] have demonstrated that ApoC-
III (or ApoC-III-rich VLDL) can stimulate VCAM-1 
and ICAM-1 expression in vascular ECs by activating 
PKCβ and NF-κB, thus suggesting a novel mechanism 
for EC activation induced by dyslipidaemia. Its ability to 
induce endothelial dysfunction was further confirmed 
by the authors, supporting the view that ApoC-III dose-
dependently attenuated insulin-stimulated eNOS activ-
ity without affecting its expression [44, 48]. Altogether, 
these findings clearly indicate that ApoC-III is a multi-
functional protein that exerts pro-inflammatory effects 
on both monocytes and ECs and suggest that targeting 
ApoC-III may not only improve lipid metabolism but 
could also prevent the development of inflamed ath-
erosclerotic plaques and their subsequent thrombotic 
complications.
In addition to the aforementioned proteins that are 
causally related to hyperlipidaemia and/or altered plasma 
lipid transport/metabolism, PCSK9 also impairs LDL-C 
clearance from the plasma, mostly by promoting LDL 
receptor degradation [49]. Here, we identified signifi-
cant up-regulation of this protein in  ApoE−/−/LDLR−/− 
plasma samples as well as in untreated FH patients’ sera. 
Interestingly, high-dose statin therapy further increased 
PCSK9 levels in patients, highlighting that PCSK9 inhibi-
tors might be a beneficial therapy for FH patients. Fur-
thermore, recent studies suggested that PCSK9 could 
accelerate atherosclerosis through mechanisms beyond 
the degradation of the hepatic LDL receptor [50, 51]. 
Tang et  al. [50] have demonstrated that PCSK9 gene 
interference could suppress atherosclerosis directly 
through decreasing vascular inflammation and inhibit-
ing the TLR4/NF-κB signalling pathway without affecting 
plasma cholesterol levels in high-fat diet-fed ApoE-defi-
cient mice. These findings strongly suggest that thera-
peutic PCSK9 inhibition may offer vascular benefits in 
addition to the reduction of plasma LDLs.
Lipoproteins retained in the arterial intima are exposed 
to oxidizing agents and enzymes that provide oxidized 
and aggregated LDL particles, which could be further 
recognized and internalized by macrophages [38]. This 
internalization is driven by the physical alteration of 
LDLs upon binding to proteoglycans, including changes 
in both ApoB/E conformation and lipid organization. The 
structural changes also make proteoglycan-bound LDLs 
more susceptible to oxidative modifications under con-
ditions of decreased activity/expression of antioxidant 
enzymes and/or decreased concentrations of low-molec-
ular-weight antioxidants. This increased susceptibility is 
consistent with our results showing that the expression 
of PON-1, catalase and GPx-3, as well as levels of several 
small-molecule antioxidants (Gln, Tau), decreased under 
pathological conditions accelerating LDL modification.
Endothelial dysfunction and diminished NO bioavailability
EC dysfunction—a harbinger of multiple CVDs, as 
diverse as hypertension, atherosclerosis, coronary artery 
disease (CAD) and diabetes mellitus, was initially identi-
fied as impaired vasodilatation to specific stimuli; how-
ever, a broader understanding of this term includes not 
only impaired vasodilation but also a pro-inflammatory 
and pro-thrombotic state of endothelial phenotype [52, 
53]. Our study shows a subset of deregulated metabo-
lites (Arg and relatives) engaged in synthesis, release 
and/or activity of endothelium-derived NO, highlight-
ing that eNOS activity and/or NO bioavailability was 
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clearly diminished in the tested models. Hence, highly 
elevated levels of Hcy which reduces DDAH (dimethylar-
ginine dimethylaminohydrolase) catabolic activity clearly 
manifest impaired this gaseous molecule availability [54]. 
Further, observed elevated plasma ApoC-III concentra-
tion seems to be a critical regulator of eNOS activity via 
preventing its phosphorylation by insulin-activated Akt, 
further leading to impaired NO generation by ECs that 
drives endothelial activation and enhances monocyte 
adherence to the vessel wall. It is not surprising, then, 
that areas of turbulent flow in the vessel wall, which have 
less endothelium-derived NO, are typically more prone 
to EC activation and atherosclerosis [55]. Indeed, our 
study supports previous observations that atherosclerotic 
lesions tend to develop in areas of vascular branching 
that are more exposed to turbulent rather than laminar 
flow [53, 55].
Interestingly, several papers reported that MNA—a 
terminal metabolite of nicotinamide clearance—at phar-
macological doses, can improve endothelial function 
in humans and in experimental animals [13, 56, 57]. 
Domagala et  al. [56] demonstrated that MNA amelio-
rated endothelial dysfunction measured as flow-mediated 
vasodilation in humans. In turn, Bar et al. [57] reported 
that MNA improved endothelial-dependent function 
in  ApoE−/−/LDLR−/− mice in  vivo, while Mateuszuk 
et al. [13] found that MNA–induced anti-atherosclerotic 
effects in  ApoE−/−/LDLR−/− mice were linked to an 
improved NO–/PGI2–dependent function. In our study, 
a massive increase in plasma MNA was a dominant fea-
ture of the metabolite profile recognized in animals fed 
the LCHP diet. This observation was supported by other 
studies demonstrating that serum MNA was strongly 
associated with the presence and severity of human CAD 
[58]. In view of these results, we suggest that the increase 
in MNA concentration in atherosclerosis might have 
compensatory and vasoprotective nature [59].
Endothelial inflammation
It is now widely accepted that atherosclerosis progres-
sion is driven by vascular inflammation (7) and the RAS, 
with its main effector—Ang II—has been recognized as 
one of the major mediators of vascular inflammation and 
atherogenesis [60]. Considerable evidence demonstrates 
that Ang II exerts its pro-inflammatory actions in the 
vascular wall by inducing the production of ROS, inflam-
matory cytokines (interleukin 6 (IL-6), monocyte chem-
oattractant protein-1 (MCP-1)) and adhesion molecules 
[60, 61]. Our studies highlighting RAS over-activation 
and, consequently, Ang II up-regulation both in an exper-
imental model of atherosclerosis and the clinical setting 
support a modulatory role for the RAS in atherogenesis.
Presently, it is well known that Ang II influences all 
inflammatory response stages that include: vascular per-
meability, leukocyte recruitment, EC activation and vas-
cular repair processes through mediators of cell growth 
and fibrosis [60]. Among the intracellular signalling path-
ways involved in Ang-II-induced vascular inflammation 
and remodelling, the production of ROS and the activa-
tion of pro-inflammatory transcription factors seem to 
play a critical role. In the vascular system, Ang II binds 
to its  AT1 receptors inducing oxidative stress, mainly 
mediated by NAD(P)H oxidase over-expression/over-
activation. In turn, increased ROS production leads to 
the uncoupling of eNOS, with a consequent decrease in 
NO bioavailability and activation of redox-sensitive pro-
inflammatory transcription factors, such as NF-κB and 
Ets1, which trigger and/or potentiate the inflammatory 
cascade [60, 61]. Various studies have highlighted that 
IL-6, secreted peripherally at the site of vascular injury, 
is a principal inducer of acute-phase protein synthesis 
through hepatocyte stimulation [60, 62]. For instance, 
IL-6 stimulates AGT, FBG, CRP, SAA and several com-
plement factors’ synthesis that propagate the downstream 
inflammatory response responsible for atherosclerosis. 
This observation is in alignment with the up-regulated 
levels of AGT, FBG and CRP/SAA that we have found 
in pathologically changed samples. Although the acute-
phase reactants are thought to restore homeostasis 
mainly through promoting the clearance of infectious 
agents or by facilitating wound repair, they also exert sig-
nificant lipid-metabolic and pro-inflammatory activities 
that, in turn, may exaggerate and sustain the process of 
atherogenesis [60]. Importantly, enhanced AGT delivery 
to the Ang II-processing enzymes present locally in the 
vasculature may further perpetuate the inflammatory 
cycle. Indeed, in our study, a positive correlation between 
circulating AGT concentrations and systemic/vascular 
Ang peptide concentrations (in  ApoE−/−/LDLR−/− mice) 
was noted. Moreover, it has recently been demonstrated 
that atherosclerotic vessels may be highly sensitive to 
locally produced Ang II as hypercholesterolemia leads 
to significant up-regulation of  AT1 gene expression [63]. 
Altogether, our results support the existence of a bio-
logical positive-feedback loop, highlighting that vascular 
inflammation can be self-sustaining through the up-regu-
lation of the vessel wall Ang II tone.
On the other hand, accumulating evidence suggests 
that CRP levels are one of the most powerful predictors 
of atherosclerosis and vascular death, offering prognos-
tic value significantly exceeding that of LDL-C [61]. The 
mechanistic basis of this predictive value of CRP might 
be linked to its ability to decrease eNOS mRNA, aug-
ment ET-1 and up-regulate diverse adhesion molecules 
and chemoattractant chemokine expression. In addition, 
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recent observations also suggest that CRP up-regulates 
NF-κB signalling in ECs, stimulates  AT1R expression in 
vascular SMCs while attenuating endothelial progenitor 
cell (EPC) differentiation, survival, and angiogenic func-
tion, and this occurs, at least in part via an effect of CRP 
to suppress EPC eNOS expression [61, 64]. In our hand, 
elevated systemic CRP level was the most characteristic 
feature identified in FH patients’ sera.
As one of the features of endothelial inflammation is 
the stimulation of endothelial expression of cell-surface 
adhesion molecules (CAMs), such as VCAM-1, ICAM-1 
and selectins that facilitate leukocyte trafficking in the 
vascular wall [61], we investigated the pattern of several 
soluble CAMs in patients with FH and ApoE/LDLR-
deficient mice. A highly elevated plasma level of sVCAM-
1, identified in  ApoE−/−/LDLR−/− mice, may serve as a 
marker of endothelial activation and local or systemic 
inflammation, whereas in humans, the level of sICAM-1 
seems to have more prognostic value in regard to athero-
sclerosis or CVD development.
Plaque formation, extracellular matrix reorganization 
and arterial remodelling
Once adherent, the monocytes transmigrate into the 
tunica intima, passing between the ECs, where they 
develop into macrophages and begin to express scaven-
ger receptors, such as LOX-1, SR-A and CD36, which 
internalize modified lipoproteins [61]. The internaliza-
tion process of these lipoprotein particles gives rise to 
lipid-laden macrophages or foam cells that characterize 
early atherosclerotic lesions. FBG, highly elevated in the 
plasma of our murine model, participates in atheroscle-
rotic plaque formation mainly through the modulation 
of endothelial function and promotion of SMC prolif-
eration and migration [65]. This glycoprotein has been 
recognized as an important component of the coagula-
tion cascade and a critical determinant of blood viscos-
ity and platelet aggregation. Although FBG and Hcy have 
both been reported as playing complementary roles in 
the platelet activation/aggregation cascade, that effect 
was attained by different mechanisms assigned to the fac-
tors investigated [66]. Furthermore, positive associations 
between plasma FBG concentrations and the risk of coro-
nary heart disease and myocardial infarction  (MI) have 
been found in several prospective epidemiological studies 
[65, 67]. However, it is still unclear whether these eleva-
tions in FBG levels are a causal factor in the development 
of atherosclerosis or, rather, an epiphenomenon of the 
atherogenic process. Our research seems to indicate that 
FBG functions as a pro-atherosclerotic factor, in addi-
tion to being a highly useful risk marker. Furthermore, 
consistent with the widely accepted assumption that 
coagulation and inflammation are not isolated elements 
because many proteins are involved in both processes, 
we have also found the down-regulated anticoagulant 
protein—VKDP-S—in FH sera that further accentuates a 
pro-thrombotic/hypercoagulable state in atherosclerosis.
During atherosclerosis progression, a decrease in the 
blood supply to the different tissues/organs may be tak-
ing place. Under conditions of ischemia, plasma/serum 
Ala appears to be increased, which may be due to myo-
cardium release through the pyruvate transamination. 
Indeed, we have found significantly elevated levels of 
Ala in the sera of FH patients as well as in pathologically 
changed murine samples.
Interestingly, in the present study, FETUB was up-reg-
ulated in  ApoE−/−/LDLR−/− plasma samples, present-
ing a similar trend to that observed in human samples, 
although variations in the concentration in FH sera (as 
compared to controls) were minor. Jung et  al. [68] have 
suggested that FETUB may be associated with ath-
erosclerotic plaque vulnerability. They demonstrated 
a significantly increased FETUB expression in serum 
from patients with acute MI as compared to those with 
stable angina. This protein accelerated monocytes/
macrophages migration and affected vascular plaque-
stabilizing factors, including lipoprotein deposition and 
cytokine production in macrophages, MMP-2 activation 
in monocytes as well as the activation of apoptosis and 
MMP-2 in VSMCs [68, 69]. Moreover, in  vivo adminis-
tration of FETUB decreased the collagen accumulation 
and SMC mobilization and showed an increased number 
of macrophages in the vascular plaque [68]. Our research 
seems to add to the above observations, suggesting a crit-
ical role for this protein in the development of acute MI. 
Adding to these findings, a significantly higher plasma 
Hyp concentration was noted in the dyslipidaemic mice 
as compared to the wild types, albeit that the differences 
in human sera were minor. According to the above obser-
vations, FETUB and Hyp could be considered as novel 
predictors of a vulnerable plaque, as well as indicators of 
an increased inflammatory status that is generally associ-
ated with higher patient susceptibility for plaque rupture.
Disruption of self‑renewal capacity of the endothelium
A variety of evidence suggests that endothelial dam-
age eventually represents a balance between the magni-
tude of injury and the capacity for repair [70]. Little is 
known regarding the mechanisms by which the vessel 
wall undergoes repair; however, there are many indica-
tions that circulating EPCs constitute one aspect of this 
repair process thereby limiting the formation of athero-
sclerotic lesions [71]. Moreover, ADMA has been rec-
ognized as an endogenous inhibitor of the mobilization, 
differentiation and function of EPCs [72], and Thum et al. 
[73] demonstrated that its high levels inversely correlated 
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with low numbers and function of EPCs in patients with 
CAD. Our data seem to support the hypothesis that an 
impaired ability to restore vascular function might accel-
erate atherogenesis as an elevated ADMA level was one 
of the most distinctive features of the plasma metabolite 
profile of animals fed an LCHP diet as compared to other 
(AIN-93G or Western) diets. Interestingly, Foo et al. [74] 
also demonstrated that an LCHP diet (in  ApoE−/− mice) 
substantially reduced the number of bone marrow and 
peripheral blood EPCs, and EPCs from these mice (on the 
LCHP diet) manifested lower levels of activated (phos-
phorylated) Akt (kinase), important in its mobilization, 
proliferation and survival. Altogether, the above obser-
vations suggest that the development of novel drugs that 
effectively reduce ADMA levels would most likely lead to 
a novel therapeutic concept in the prevention and treat-
ment of atherosclerosis (or CAD) based on the improved 
mobilization and function of EPCs, thus strengthening 
the vascular regenerative capacity.
Limitations of the study
The authors are aware that extrapolating of the results 
gathered in mice models to human medicine has a num-
ber of limitations but rapid mice reproduction, ease of 
their genetic manipulation and rapid atherogenesis devel-
opment in murine models are undisputable [75]. Here, we 
used ApoE/LDLR−/− mice as they develop more severe 
hyperlipidaemia and atherosclerosis than single knock-
outs  (ApoE−/− or  LDLR−/−, respectively) without a need 
of Western diet, and display a similar pattern of vascular 
inflammation and atherogenesis as humans [11, 15, 75]. 
Indeed,  LDLR−/− mice, compared to  ApoE−/− or ApoE/
LDLR−/−, display modestly elevated plasma cholesterol 
levels and develop only mild atherosclerosis when fed a 
normal diet; however, they are highly responsive to high-
fat/high cholesterol Western-type diets that affect the 
lipoprotein profile of these mice, amplifying atheroscle-
rotic lesion development. Nonetheless,  LDLR−/− mice 
possess some advantages over  ApoE−/− mice in terms of 
comparison with human FH: (1) a more human-like lipid 
profile (as plasma cholesterol is carried more by LDL 
than in HDL particles but still not identical with typi-
cal human-like lipid pattern as reproduced in E3L.CETP 
mice [76]), (2) targeted inactivation of the LDL receptor 
does not impact inflammation as the deletion of ApoE, 
and (3) this model shares the characteristics observed in 
human FH (mutations in LDLR gene) [11, 75]. Although 
our study demonstrates a relative agreement between 
species in terms of multi-omic signature identified, some 
caution should be taken in extrapolating the results from 
animals to humans. More precisely, an estimated 70–95% 
of FH results from a heterozygous pathogenic variant in 
one of the following genes—LDLR, APOB, PCSK9—with 
the first one accounting for approximately 80% of FH 
[77]. Homozygous FH (HoFH) with pathogenic variants 
in one of these known genes (LDLR, APOB, PCSK9) 
affects a lower proportion of the population and is mani-
fested by severe CAD (typically by the mid-20  s) and a 
high rate of either death or coronary bypass surgery. In 
contrast, in the current study, homozygous mice for the 
disrupted ApoE and LDLR genes were used, which obvi-
ously cannot reflect FH disease phenotype.
In the current work, the authors employed the classic 
targeted quantification assay using SRM mode with the 
aim of performing a precisely targeted measurement of 
dozens of metabolites in the matrix evaluated. However, 
we are aware that the utilization of this strategy in bio-
logical studies might be limited/not optimal due to its 
relatively low metabolite coverage and throughput capac-
ity. Nevertheless, in modern metabolomics compromises 
must be reached when selecting among the features for 
analysis performance, including metabolite coverage, 
throughput, specificity, accuracy and feasibility for spe-
cific approaches, and adjustments in strategies must be 
attained depending on the analytical goals. AAs and their 
derivatives were selected as the subject of the study as 
abundant evidence indicated that they play a fundamen-
tal role in cardiovascular physiology and pathology [78]. 
Decades of research have established the importance of 
L-Arg, L-Gln, L-Trp and L-Cys in modulating vascular 
function via the formation of a myriad of metabolites, 
including a number of gases (nitric oxide, carbon mon-
oxide, ammonia, hydrogen sulphide and sulphur diox-
ide) [78, 79]. The metabolism of AAs has been causally 
linked to the regulation of vascular homeostasis as well 
as immune cell function. Moreover, there is an emerg-
ing recognition that circulating levels of multiple AAs 
are altered in vascular-related disorders and that a more 
holistic approach that targets all of these AA derange-
ments is required to restore circulatory function in blood 
vessels affected by lipid abnormalities [79]. Nonetheless, 
the recent advances in LC/MS instruments and analytical 
strategies have brought substantial progress in targeted 
metabolomics determinations, and new approaches in 
this field have enabled expanding the options for large-
scale targeted metabolomics analyses that employ high-
resolution instruments with parallel reaction monitoring 
(PRM) mode [80]. The strategies based on high-res/PRM 
techniques now constitute attractive modalities for quan-
titative metabolomics analysis and high-throughput bio-
marker discovery.
In addition, plasma samples have been used for -omics 
evaluations in experimental models, whereas in humans, 
serum was applied that could also have affected the qual-
ity or integrity of the data as well as the final conclusions. 
Albeit that several previous studies have clearly indicated 
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that many target clinical parameters, such as metal ions 
and proteins/enzymes may possess different concentra-
tions in the two different media, the composition of small 
molecules in plasma and serum is considered to be highly 
similar [81–83]. Some studies have also demonstrated 
that on a global level, metabolite association networks 
from plasma and serum fractions that were collected 
from the same individuals presented similar topologies, 
and only at a local level did some differences arise that 
were seen in higher concentrations of selected metabo-
lites in serum than in plasma (which should be taken into 
account when analysing, comparing and interpreting the 
data) [84]. However, as we are more interested in the rela-
tionships among metabolite concentration levels rather 
than in their levels alone (at least in the context of our 
study), as long as the same blood preparation procedure 
is used, either matrix—plasma or serum—should gener-
ate similar results in (pre)clinical studies. On the other 
hand, it was also suggested that the lower protein content 
in serum might benefit metabolite analyses and improve 
the overall sensitivity, making serum more applicable for 
high-throughput biomarker profiling [81, 85]. Addition-
ally, as different collection procedures and the coagu-
lation cascade influence the fibrinogen and associated 
proteins [82], those were specifically excluded from the 
investigations of clinical samples to avoid sample-related 
biases in biomarker studies.
In recent years, high-throughput omics technolo-
gies, frequently defined as high-throughput biochemical 
assays, have provided an unprecedented opportunity to 
depict the biological system under investigation at multi-
ple molecular levels [86–88]. However, the complexity of 
managing and integrating such multi-omics datasets con-
tinues to be a challenge, and the development of reliable 
strategies that can successfully tackle that complexity of 
multi-dimensional data is critical for gaining actionable 
knowledge in a precision medicine framework. Those 
recent data-driven methodologies/innovations (such as 
machine learning methodologies or network-based meth-
ods) have been developed/applied to respond to major 
challenges of stratified medicine, including patients’ phe-
notyping, biomarker discovery and drug repurposing; 
however, some constraints associated with the availability 
of the data for single omics individually, hosting options 
not dedicated for the multi-platform/multi-layered data, 
and the lack of relevant guidelines for quality and valida-
tion of data consistency should be improved before those 
tools might be deemed effective in a clinically meaning-
ful way [86–88]. The authors are also aware of some limi-
tations of the experimental design proposed as well as 
data accessibility in the current study. More specifically, 
the high-throughput sequencing technology was only 
applied in animal studies, thus providing limited insights 
into the complexity of biological processes. We also 
understand that only integrated approaches (based on 
complete multi-omics datasets) allow for comprehensive 
views of genetic, biochemical, proteomic and metabolic 
processes underlying the disease. However, considering 
an extrapolation of the approach selected to larger bio-
logical cohorts and multifaceted experimental designs in 
which a plethora of samples would need to be analysed 
in a realistic timeline, the feasibility of gathering clini-
cally meaningful information was attained, and our study 
could be a starting point for more holistic investigations.
Conclusions
Despite a number of limitations of this work, we iden-
tified 15 metabolites and 9 proteins as key molecular 
alterations in underlying atherogenic dyslipidaemia. 
Those metabolites/proteins were mainly related to lipid 
metabolism, LDL retention, oxidative stress, endothelial 
inflammation, hypercoagulation, arterial remodelling, 
activation of response to ischemia as well as impairment 
in the vascular regenerative capacity. A specific molecu-
lar panel, recognized here, could be proposed to monitor 
atherosclerosis development and progression to predict 
potential cardiovascular risk. However, as the vascular 
changes were not followed in patients that we studied, 
further analysis is necessary to confirm the relation of 
chosen biomarkers with the progression of clinical ath-
erosclerosis. If these preliminary results are confirmed 
in a larger cohort of patients and its relation to clinical 
presentation in long-term analysis, they may be valuable 
for personalized prevention of dyslipidaemia-induced 
atherosclerosis.
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